BioCentury | Feb 2, 2018
Clinical News

Takeda, Zinfandel's AD test fails to deliver

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial...
...Study-Activities of Daily Living-Prevention Instrument (ADCS-ADL-PI) Status: Phase III discontinued Milestone: NA Meghan Sullivan Actos pioglitazone Takeda Pharmaceutical Co. Ltd. Zinfandel Pharmaceuticals Inc. Peroxisome...
BioCentury | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

...Reminyl galantamine, an AChE inhibitor and nicotinic receptor modulator; and a diagnostic it licensed from Zinfandel Pharmaceuticals Inc....
...discovered using Evotec's EVOlution screening platform CNS and metabolic indications Preclinical Undisclosed Undisclosed Jan. 2011 Zinfandel Pharmaceuticals Inc....
...Co. Ltd. (TOKYO:4502), Osaka, Japan Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), Petach Tikva, Israel Zinfandel Pharmaceuticals...
BioCentury | Jan 25, 2018
Clinical News

Takeda, Zinfandel’s AD test fails to deliver

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMORROW trial...
...candidates, plus an undisclosed discovery-stage program (see BioCentury Innovations, Jan. 25) . Meghan Sullivan pioglitazone Takeda Pharmaceutical Co. Ltd. Zinfandel Pharmaceuticals Inc. Peroxisome...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...green). The most advanced of the tests with a novel target (shown in gold) is Zinfandel Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Clinical News

Biomarker risk assignment algorithm: Phase III started

...PPV) of 79% and a negative predictive value (NPV) of 44% (see BioCentury, Aug. 5). Zinfandel Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Clinical News

Actos pioglitazone: Phase III started

...Takeda and Zinfandel Pharmaceuticals Inc. (Durham, N.C.) began the double-blind, international Phase III TOMMORROW trial of oral AD-4833...
BioCentury | Aug 5, 2013
Clinical News

Biomarker risk assignment algorithm diagnostic data

...information from 200 normal volunteers, 400 people with MCI and 200 patients with early AD. Zinfandel Pharmaceuticals Inc....
BioCentury | Jan 17, 2011
Company News

Zinfandel Pharmaceuticals, Takeda deal

...The product is a thiazolidinedione (TZD) peroxisome proliferation activated receptor (PPAR) gamma agonist insulin sensitizer. Zinfandel Pharmaceuticals Inc....
BioCentury | Jan 12, 2011
Company News

Takeda, Zinfandel in AD biomarker deal

Zinfandel Pharmaceuticals Inc. (Durham, N.C.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive, worldwide rights to develop and commercialize an assay to detect variants of the translocase of outer mitochondrial membrane 40 homolog ( TOMM40 ; TOM40...
BioCentury | Sep 3, 2009
Distillery Therapeutics

Indication: Neurology

...steps could include using this information to stratify patients in AD trials by TOMM40 genotype. Zinfandel Pharmaceuticals Inc....
Items per page:
1 - 10 of 12
BioCentury | Feb 2, 2018
Clinical News

Takeda, Zinfandel's AD test fails to deliver

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMMORROW trial...
...Study-Activities of Daily Living-Prevention Instrument (ADCS-ADL-PI) Status: Phase III discontinued Milestone: NA Meghan Sullivan Actos pioglitazone Takeda Pharmaceutical Co. Ltd. Zinfandel Pharmaceuticals Inc. Peroxisome...
BioCentury | Jan 25, 2018
Strategy

Takeda rides Denali’s ATV

...Reminyl galantamine, an AChE inhibitor and nicotinic receptor modulator; and a diagnostic it licensed from Zinfandel Pharmaceuticals Inc....
...discovered using Evotec's EVOlution screening platform CNS and metabolic indications Preclinical Undisclosed Undisclosed Jan. 2011 Zinfandel Pharmaceuticals Inc....
...Co. Ltd. (TOKYO:4502), Osaka, Japan Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA), Petach Tikva, Israel Zinfandel Pharmaceuticals...
BioCentury | Jan 25, 2018
Clinical News

Takeda, Zinfandel’s AD test fails to deliver

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and partner Zinfandel Pharmaceuticals Inc. (Durham, N.C.) discontinued the Phase III TOMORROW trial...
...candidates, plus an undisclosed discovery-stage program (see BioCentury Innovations, Jan. 25) . Meghan Sullivan pioglitazone Takeda Pharmaceutical Co. Ltd. Zinfandel Pharmaceuticals Inc. Peroxisome...
BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...green). The most advanced of the tests with a novel target (shown in gold) is Zinfandel Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Clinical News

Biomarker risk assignment algorithm: Phase III started

...PPV) of 79% and a negative predictive value (NPV) of 44% (see BioCentury, Aug. 5). Zinfandel Pharmaceuticals Inc....
BioCentury | Sep 16, 2013
Clinical News

Actos pioglitazone: Phase III started

...Takeda and Zinfandel Pharmaceuticals Inc. (Durham, N.C.) began the double-blind, international Phase III TOMMORROW trial of oral AD-4833...
BioCentury | Aug 5, 2013
Clinical News

Biomarker risk assignment algorithm diagnostic data

...information from 200 normal volunteers, 400 people with MCI and 200 patients with early AD. Zinfandel Pharmaceuticals Inc....
BioCentury | Jan 17, 2011
Company News

Zinfandel Pharmaceuticals, Takeda deal

...The product is a thiazolidinedione (TZD) peroxisome proliferation activated receptor (PPAR) gamma agonist insulin sensitizer. Zinfandel Pharmaceuticals Inc....
BioCentury | Jan 12, 2011
Company News

Takeda, Zinfandel in AD biomarker deal

Zinfandel Pharmaceuticals Inc. (Durham, N.C.) granted Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) exclusive, worldwide rights to develop and commercialize an assay to detect variants of the translocase of outer mitochondrial membrane 40 homolog ( TOMM40 ; TOM40...
BioCentury | Sep 3, 2009
Distillery Therapeutics

Indication: Neurology

...steps could include using this information to stratify patients in AD trials by TOMM40 genotype. Zinfandel Pharmaceuticals Inc....
Items per page:
1 - 10 of 12